Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine
Dates
study started
study ends around
Principal Investigator
by Piyanuch Kongtim (uci)
Headshot of Piyanuch Kongtim
Piyanuch Kongtim

Description

Summary

This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.

Official Title

Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

Keywords

CMV, Allogeneic Stem Cell Transplantation, CMV T Cell Immunity Panel, CMV reactivation, Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR, AHCT recipients

Eligibility

Location

  • Chao Family Comprehensive Cancer Center, University of California Irvine accepting new patients
    Orange California 92868 United States

Lead Scientist at University of California Health

  • Piyanuch Kongtim (uci)
    Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 64 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT06453460
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated